Disc Medicine (IRON) News Today → Next President (Not Trump. Not Biden.) (From The Freeport Society) (Ad) Free IRON Stock Alerts $32.18 +0.26 (+0.81%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 17 at 4:50 AM | americanbankingnews.comCantor Fitzgerald Reiterates Overweight Rating for Disc Medicine (NASDAQ:IRON)May 15, 2024 | marketbeat.comFirst Turn Management LLC Purchases Shares of 157,274 Disc Medicine, Inc. (NASDAQ:IRON)First Turn Management LLC purchased a new stake in Disc Medicine, Inc. (NASDAQ:IRON - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 157,274 shares of the company's stock, valued at appMay 15, 2024 | markets.businessinsider.comCantor Fitzgerald Keeps Their Buy Rating on Disc Medicine (IRON)May 15, 2024 | marketbeat.comCantor Fitzgerald Reaffirms "Overweight" Rating for Disc Medicine (NASDAQ:IRON)Cantor Fitzgerald restated an "overweight" rating and set a $85.00 price target on shares of Disc Medicine in a research note on Wednesday.May 14, 2024 | marketbeat.comNicholas Investment Partners LP Makes New Investment in Disc Medicine, Inc. (NASDAQ:IRON)Nicholas Investment Partners LP bought a new stake in shares of Disc Medicine, Inc. (NASDAQ:IRON - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The fund bought 40,494 shares of the company's stock, valued at approximately $2,339,000. Nicholas Investment ParMay 14, 2024 | globenewswire.comDisc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2024 CongressMay 14, 2024 | americanbankingnews.comDisc Medicine (NASDAQ:IRON) Given New $43.00 Price Target at Raymond JamesMay 13, 2024 | washingtonpost.comShould I take an iron supplement? Here’s what the science says.May 13, 2024 | globenewswire.comDisc Medicine to Participate in the H.C. Wainwright BioConnect Investor ConferenceMay 13, 2024 | americanbankingnews.comDisc Medicine's (IRON) "Buy" Rating Reiterated at HC WainwrightMay 13, 2024 | marketbeat.comVictory Capital Management Inc. Grows Stock Holdings in Disc Medicine, Inc. (NASDAQ:IRON)Victory Capital Management Inc. boosted its holdings in Disc Medicine, Inc. (NASDAQ:IRON - Free Report) by 36.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 187,580 shares of the company's stock after buying an adMay 13, 2024 | americanbankingnews.comLifesci Capital Weighs in on Disc Medicine, Inc.'s Q2 2024 Earnings (NASDAQ:IRON)May 11, 2024 | finance.yahoo.comDisc Medicine Inc (IRON) Reports Q1 2024 Earnings: A Detailed Financial OverviewMay 10, 2024 | marketbeat.comDisc Medicine (NASDAQ:IRON) Price Target Increased to $43.00 by Analysts at Raymond JamesRaymond James lifted their price objective on shares of Disc Medicine from $40.00 to $43.00 and gave the company an "outperform" rating in a research report on Friday.May 10, 2024 | marketbeat.comDisc Medicine (NASDAQ:IRON) Rating Reiterated by HC WainwrightHC Wainwright restated a "buy" rating and issued a $70.00 price objective on shares of Disc Medicine in a research report on Friday.May 10, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Electrocore (ECOR), Disc Medicine (IRON) and Allakos (ALLK)May 10, 2024 | markets.businessinsider.comOptimistic Buy Rating for Disc Medicine Amid Anticipated Study Results and Strong Financial PositionMay 9, 2024 | finanznachrichten.deDisc Medicine Inc: Disc Medicine Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 9, 2024 | globenewswire.comDisc Medicine Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 1, 2024 | msn.com29 incredible ancient wonders that are even older than you thinkApril 27, 2024 | marketbeat.com43,031 Shares in Disc Medicine, Inc. (NASDAQ:IRON) Bought by Jennison Associates LLCJennison Associates LLC acquired a new stake in shares of Disc Medicine, Inc. (NASDAQ:IRON - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 43,031 shares of the company's stock, valued at approximatelApril 19, 2024 | marketbeat.comDisc Medicine (NASDAQ:IRON) Shares Down 4.1% Disc Medicine (NASDAQ:IRON) Shares Down 4.1%April 17, 2024 | msn.comDisc Medicine (IRON) Price Target Decreased by 29.78% to 58.25April 16, 2024 | insidertrades.comDisc Medicine, Inc. (NASDAQ:IRON) Director William Richard White Sells 2,560 SharesApril 15, 2024 | marketbeat.comInsider Selling: Disc Medicine, Inc. (NASDAQ:IRON) Director Sells 2,560 Shares of StockDisc Medicine, Inc. (NASDAQ:IRON - Get Free Report) Director William Richard White sold 2,560 shares of the stock in a transaction on Thursday, April 11th. The shares were sold at an average price of $31.80, for a total value of $81,408.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.April 14, 2024 | marketbeat.comDisc Medicine, Inc. (NASDAQ:IRON) Sees Large Growth in Short InterestDisc Medicine, Inc. (NASDAQ:IRON - Get Free Report) was the target of a large increase in short interest in the month of March. As of March 31st, there was short interest totalling 1,860,000 shares, an increase of 47.6% from the March 15th total of 1,260,000 shares. Based on an average daily volume of 431,300 shares, the short-interest ratio is currently 4.3 days.April 12, 2024 | msn.comPerformance Coupe Showdown: 2023 BMW M2 vs. 2024 Ford Mustang Dark HorseApril 12, 2024 | marketbeat.comDisc Medicine, Inc. (NASDAQ:IRON) Shares Purchased by Vanguard Group Inc.Vanguard Group Inc. boosted its stake in shares of Disc Medicine, Inc. (NASDAQ:IRON - Free Report) by 18.9% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 665,452 shares of the company's stock after acquiring an additional 105,685 shares during the periodApril 9, 2024 | msn.comExplore Outdoors: Step into a 5,000-year-old Native American kitchen in RocklinApril 8, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Legend Biotech (LEGN), Intuitive Surgical (ISRG) and Disc Medicine (IRON)April 8, 2024 | marketbeat.comDisc Medicine (NASDAQ:IRON) Price Target Increased to $73.00 by Analysts at Stifel NicolausStifel Nicolaus increased their price objective on Disc Medicine from $71.00 to $73.00 and gave the company a "buy" rating in a research note on Monday.April 4, 2024 | marketbeat.comDisc Medicine, Inc. (NASDAQ:IRON) Receives Consensus Rating of "Moderate Buy" from BrokeragesDisc Medicine, Inc. (NASDAQ:IRON - Get Free Report) has earned an average recommendation of "Moderate Buy" from the eight brokerages that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a hold recommendation and seven have given a buy recommendation toApril 2, 2024 | marketbeat.comMorgan Stanley Trims Disc Medicine (NASDAQ:IRON) Target Price to $40.00Morgan Stanley decreased their price objective on shares of Disc Medicine from $75.00 to $40.00 and set an "equal weight" rating on the stock in a report on Tuesday.April 2, 2024 | msn.comTop 3 Health Care Stocks You'll Regret Missing This MonthApril 2, 2024 | marketbeat.comDisc Medicine (NASDAQ:IRON) Shares Down 7.5% Following Analyst DowngradeDisc Medicine (NASDAQ:IRON) Trading Down 7.5% Following Analyst DowngradeApril 2, 2024 | marketbeat.comDisc Medicine, Inc. (NASDAQ:IRON) Short Interest UpdateDisc Medicine, Inc. (NASDAQ:IRON - Get Free Report) was the target of a large growth in short interest in the month of March. As of March 15th, there was short interest totalling 1,260,000 shares, a growth of 5.9% from the February 29th total of 1,190,000 shares. Based on an average trading volume of 290,000 shares, the days-to-cover ratio is presently 4.3 days.April 1, 2024 | markets.businessinsider.comMaintaining Buy Rating: Bitopertin’s Efficacy in EPP Despite AURORA Study’s Placebo ResponseApril 1, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Disc Medicine (IRON) and Erasca (ERAS)April 1, 2024 | msn.comDisc Medicine Stock Plunges As Light Sensitivity Treatment Data Confounded Due To Outsized Placebo ResponseApril 1, 2024 | markets.businessinsider.comDisc Medicine Tanks 55% On Announcement Of Phase 2 AURORA Topline Data Regarding BitopertinApril 1, 2024 | finance.yahoo.comDisc Medicine Plummets After Placebo Effect Confounds Sunlight Sensitivity StudyApril 1, 2024 | marketbeat.comDisc Medicine (NASDAQ:IRON) Earns "Outperform" Rating from WedbushWedbush restated an "outperform" rating and set a $43.00 price target (down previously from $84.00) on shares of Disc Medicine in a research note on Monday.April 1, 2024 | marketbeat.comDisc Medicine (NASDAQ:IRON) Shares Gap Down to $62.26Disc Medicine (NASDAQ:IRON) Shares Gap Down to $62.26April 1, 2024 | markets.businessinsider.comDisc Medicine Reports Topline Results From Phase 2 AURORA Study Of Bitopertin - Quick FactsApril 1, 2024 | finance.yahoo.comDisc Medicine Plummets 59% After Placebo Effect Confounds Sunlight Sensitivity StudyApril 1, 2024 | globenewswire.comDisc Reports Topline Results from Phase 2 AURORA Study of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP)April 1, 2024 | marketbeat.comTrading was temporarily halted for "IRON" at 07:04 AM with a stated reason of "News pending."March 25, 2024 | markets.businessinsider.comBuy Rating for Disc Medicine on Promising Bitopertin Trials and Robust Hematology PipelineMarch 23, 2024 | finance.yahoo.comDisc Medicine Inc (IRON) Reports Earnings: A Detailed Look at Fiscal PerformanceMarch 22, 2024 | markets.businessinsider.comBuy Rating Affirmed: Promising Trials and Market Potential for Disc Medicine’s Bitopertin Get Disc Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for IRON and its competitors with MarketBeat's FREE daily newsletter. Email Address The Overlooked Retirement Asset You Probably Don’t Own (Ad)4 out of 5 Americans believe we’re on the brink of a retirement crisis. Luckily, in these unprecedented times, we have an unprecedented solution. Once considered a “fringe” investment, the crypto market is now taking the world by storm. Click here to access the Crypto Retirement Blueprint now. IRON Media Mentions By Week IRON Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IRON News Sentiment▼0.620.42▲Average Medical News Sentiment IRON News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IRON Articles This Week▼163▲IRON Articles Average Week Get Disc Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for IRON and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Praxis Precision Medicines News ALX Oncology News Longboard Pharmaceuticals News Evolus News Arcturus Therapeutics News Tango Therapeutics News Dianthus Therapeutics News PureTech Health News Zentalis Pharmaceuticals News Aurinia Pharmaceuticals News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IRON) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 Media41 banks launch ‘crypto dollar’Stansberry ResearchExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersBuy this small stock before coming AI Tidal WaveChaikin AnalyticsUrgent Nvidia WarningAltimetryForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressMost important medical advance in 100 yearsThe Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Disc Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
